Abstract: The present invention provides methods of manufacturing a sterile ciclesonide-containing aqueous suspension comprising the step of sterilization by autoclaving a ciclesonide-containing aqueous suspension.

Abstract: The present invention provides a ciclesonide-containing sterile aqueous suspension sterilized by autoclaving, wherein the concentration of ciclesonide after autoclaving is 95% or more compared to that before autoclaving.

Abstract: The present invention provides methods of manufacturing a sterile ciclesonide-containing aqueous suspension comprising the step of sterilization by autoclaving a ciclesonide-containing aqueous suspension.

Abstract: The present invention provides a ciclesonide-containing sterile aqueous suspension sterilized by autoclaving, wherein the concentration of ciclesonide after autoclaving is 95% or more compared to that before autoclaving, as well as methods of manufacturing a ciclesonide-containing sterile aqueous suspension comprising the step of sterilization by autoclaving a ciclesonide-containing aqueous suspension.

Abstract: There is provided a powder composition for nasal administration comprising a drug having a particle size of less than 10 &mgr;m or a lyophilized drug, a water-absorbing and water-slightly soluble base material, and a water-absorbing and gel-forming base materials. The composition has excellent drug absorbability.

Abstract: A powdered medicine multi-dose administering device in which a hole (5c) is formed in the bottom surface of a medicine storage chamber (5a) capable of storing a powdered medicine of an amount of many times of administering operation, the hole (5c) being located at a position where a pump unit can be communicated with the exterior via a pipe (2g, 2d). At the administering position, the powdered medicine in a medicine container unit (5b) is injected out of the device together with the air through the pipe, while the hole is kept away from being brought into contact with opening means (2f).

Abstract: A pharmaceutical composition comprising a biphenylamidine derivative, particles for nucleus and a binder. Specifically, a pharmaceutical composition obtained by coating the particles for nucleus with the biphenylamidine derivative and the binder.

Abstract: A powdered medicine multi-dose administering device has a medicine container unit (5b) for containing a unit-dose of medicine under the lower surface of the medicine storage chamber (5a) storing the medicine in a multi-dose amount. A medicine guiding unit (2) moves between a filling position and an administering position while maintaining a contact with the bottom surface. At the filling position, the medicine container unit is opened to the medicine storage chamber and is filled with the medicine. As the medicine container unit moves from the filling position to the administering position, the powdered medicine in the medicine container unit is swept and metered. At the administering position, the medicine in the medicine container unit is injected by the action of the pump unit (3) through a filter (6) and a pipe (2g, 2d, 2c).

Abstract: A powdered medicine multi-dose administering device in which a hole (5c) is formed in the bottom surface of a medicine storage chamber (5a) capable of storing a powdered medicine of an amount of many times of administering operation, the hole (5c) being located at a position where a pump unit can be communicated with the exterior via a pipe (2g, 2d). At the administering position, the powdered medicine in a medicine container unit (5b) is injected out of the device together with the air through the pipe, while the hole is kept away from being brought into contact with opening means (2f).

Abstract: A powdery nasal composition comprising a drug and colloidal cellulose is provided. The composition is a nasal composition providing a superior absorption activity for the drug.

Abstract: Vitamin B.sub.12 compounds, salts and pharmaceutical compositions containing said compounds represented by formula (I): ##STR1## wherein L, a ligand to the cobalt of the corrin ring, is selected from the group consisting of a cyano or adenosyl group, B is an imidazole group or a 5,6-dimethylbenzimidazole group, and R is a straight alkylene group having 1 to 8 carbon atoms, are disclosed. Methods for preparing compounds of Formula (I) as well as methods for using the compounds in in vitro assays, in cell growth studies and in in vivo studies using transplanted murine tumor cells are disclosed.

Abstract: A 4H-3,1-benzoxazin-4-one compound of the formula (I): ##STR1## wherein R is a hydrogen atom or alkyl radical, A is an amino acid residue or a peptide having 2 to 3 amino acid residues, which amino acid residue may have a side chain thereof protected by a protective radical, X is an alkyl, fluoroalkyl, OR.sup.1 or NHR.sup.1 radical wherein R.sup.1 is an alkyl radical, and Y is a protective radical for an amino radical, and salts thereof, exhibit an excellent inhibitory activity against serine proteases, especially against human leukocyte elastase, and thus are useful as an effective component of a medicine for inhibiting elastase.